Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 280,428 shares of the company's stock after acquiring an additional 41,686 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.62% of Apogee Therapeutics worth $16,472,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in APGE. California State Teachers Retirement System raised its position in Apogee Therapeutics by 25.6% in the 1st quarter. California State Teachers Retirement System now owns 23,002 shares of the company's stock valued at $1,528,000 after purchasing an additional 4,693 shares in the last quarter. Comerica Bank boosted its position in shares of Apogee Therapeutics by 6,103.8% during the 1st quarter. Comerica Bank now owns 6,576 shares of the company's stock worth $437,000 after acquiring an additional 6,470 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Apogee Therapeutics in the 2nd quarter valued at about $143,000. Principal Financial Group Inc. increased its holdings in shares of Apogee Therapeutics by 26.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock valued at $253,000 after acquiring an additional 1,340 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Apogee Therapeutics by 56.8% during the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company's stock worth $6,149,000 after acquiring an additional 56,607 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 6,665 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80. Following the completion of the sale, the insider now owns 267,463 shares of the company's stock, valued at $15,812,412.56. This represents a 2.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the company's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total value of $2,249,200.00. Following the transaction, the chief executive officer now directly owns 1,354,487 shares of the company's stock, valued at $76,162,804.01. This trade represents a 2.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,995 shares of company stock valued at $4,912,264. 36.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

APGE has been the topic of several recent analyst reports. Wedbush increased their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a research note on Monday, December 2nd. Guggenheim reaffirmed a "buy" rating and issued a $110.00 target price (up from $95.00) on shares of Apogee Therapeutics in a research report on Tuesday, December 3rd. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics currently has an average rating of "Buy" and an average target price of $83.88.

Apogee Therapeutics Stock Up 6.0 %

Shares of Apogee Therapeutics stock traded up $2.81 during trading on Friday, hitting $49.97. 438,600 shares of the company were exchanged, compared to its average volume of 504,758. Apogee Therapeutics, Inc. has a fifty-two week low of $19.91 and a fifty-two week high of $72.29. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -20.65 and a beta of 2.30. The firm has a 50 day moving average price of $52.41 and a 200 day moving average price of $48.30.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.